Clinical Trial Update: Randomized Phase III of PRRT Versus Interferon [Phase 3]

View source ↗

Summary

A Phase III randomized trial comparing peptide receptor radionuclide therapy (PRRT) to Interferon for gastrointestinal neuroendocrine tumors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neuroendocrine Tumor

Drugs mentioned

• Interferon Alfa (interferon alfa)
• PRRT (peptide receptor radionuclide therapy)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Gastro-intestinal Neuroendocrine Tumors | Phase 3 | Status: WITHDRAWN